This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Impaired Immunogenicity to COVID-19 Vaccines in Autoimmune Systemic Diseases - High Prevalence of Non-Response in Different Patients’ Subgroups (preprint)
ssrn; 2021.
Preprint
in English
| PREPRINT-SSRN | ID: ppzbmed-10.2139.ssrn.3942651
ABSTRACT
Background:
Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines . Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19.Methods:
The study included 478 unselected ASD patients (mean age 59±15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59±14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle.Findings:
The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53-1203) vs 825 (451-1542) BAU/mL, p<0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p<0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p=.009), and in those treated with glucocorticoids (p=.002), mycophenolate-mofetil (pInterpretations Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine; while a different type of vaccine could be administered to non-responder individuals.Funding Information None.Declaration of Interests The authors do not have conflict of interest.Ethics Approval Statement The study protocol was approved by local ethic committee (RETRO-CoV2 study code #17886_bio); informed consent was obtained from all patients before participation.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-SSRN
Main subject:
Arthritis, Rheumatoid
/
Scleroderma, Systemic
/
Autoimmune Diseases
/
Vasculitis
/
Systemic Vasculitis
/
COVID-19
/
Laboratory Infection
/
Lupus Erythematosus, Systemic
Language:
English
Year:
2021
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS